Peptides  ›  Survodutide  ›  Fat Loss
Metabolic

Survodutide for Fat Loss: What the Research Says

Clinical trials — investigational.Updated August 2026

Survodutide (also known as BI 456906) is an investigational GLP-1/glucagon dual agonist studied for weight and liver health. This page covers what the published research does — and does not — establish about it in relation to fat loss and weight management.

What the research covers

Survodutide is researched for Weight management, Metabolic health — which is why it appears in discussions of fat loss and weight management.

Research status: Clinical trials — investigational.

How Survodutide is thought to work

Survodutide is an investigational dual agonist of the GLP-1 and glucagon receptors. Combining appetite regulation with glucagon-driven energy expenditure, it is under study for obesity and for metabolic-associated fatty liver disease (MASH).

What it does not establish

Not approved. Investigational compound; use only under medical supervision.

Nothing on this page is a recommendation to use Survodutide, and Selpho publishes no dosing, reconstitution or sourcing information. Read how we decide what goes in the library.

Other peptides researched for Fat Loss

A GLP-1 receptor agonist approved for type 2 diabetes and weight management.

A dual GIP/GLP-1 receptor agonist approved for diabetes and weight management.

An investigational triple GIP/GLP-1/glucagon agonist studied for weight loss.

A long-acting amylin analog studied for appetite and weight, often with semaglutide.

A growth-hormone fragment studied for fat metabolism.

A mitochondrial-derived peptide studied for metabolism and exercise.

Frequently asked questions

Clinical trials — investigational. Research relevant to this area covers weight management, metabolic health. That is a description of where the research points, not evidence that it will work for you — and Selpho does not provide dosing or medical advice.

Clinical trials — investigational.

Not approved. Investigational compound; use only under medical supervision. Always speak to a licensed healthcare professional before considering any peptide.

Weight management, liver health (MASH), and broader metabolic outcomes. It is investigational.

It activates both GLP-1 and glucagon receptors, whereas semaglutide targets GLP-1 alone. It is still in clinical development.

Is Survodutide right for your situation?

Describe your goals and the free Peptide Advisor will match them against the research — no signup, no sales pitch.

Ask the Advisor — free

This page is for educational purposes only and is not medical advice, a diagnosis, or a recommendation to use any compound. It contains no dosing or purchase information. Always consult a licensed healthcare professional before considering any peptide.